Early-onset vasomotor symptoms and development of depressive symptoms among premenopausal women

We investigated the association between vasomotor symptoms (VMSs) and the onset of depressive symptoms among premenopausal women. This cross-sectional study included 4376 premenopausal women aged 42–52 years, and the cohort study included 2832 women without clinically relevant depressive symptoms at...

Full description

Saved in:
Bibliographic Details
Published in:Journal of affective disorders 2024-06, Vol.354, p.376-384
Main Authors: Choi, Hye Rin, Chang, Yoosoo, Park, Jungeun, Cho, Yoosun, Kim, Chanmin, Kwon, Min-Jung, Kang, Jeonggyu, Kwon, Ria, Lim, Ga-young, Ahn, Jiin, Kim, Kye-Hyun, Kim, Hoon, Hong, Yun Soo, Park, Jihwan, Zhao, Di, Cho, Juhee, Guallar, Eliseo, Park, Hyun-Young, Ryu, Seungho
Format: Article
Language:English
Subjects:
Cohort Studies
Cross-Sectional Studies
Depression - epidemiology
Depressive symptom
Female
Hot flash
Hot Flashes - epidemiology
Humans
Menopause
Menopause transition
Middle Aged
Night sweat
Sleep quality
Sweating
Vasomotor symptom
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the association between vasomotor symptoms (VMSs) and the onset of depressive symptoms among premenopausal women. This cross-sectional study included 4376 premenopausal women aged 42–52 years, and the cohort study included 2832 women without clinically relevant depressive symptoms at baseline. VMSs included the symptoms of hot flashes and night sweats. Depressive symptoms were evaluated using the Center for Epidemiological Studies Depression Scale; a score of ≥16 was considered to define clinically relevant depressive symptoms. Premenopausal Women with VMSs at baseline exhibited a higher prevalence of depressive symptoms compared with women without VMSs at baseline (multivariable-adjusted prevalence ratio 1.76, 95 % confidence interval [CI] 1.47–2.11). Among the 2832 women followed up (median, 6.1 years), 406 developed clinically relevant depressive symptoms. Women with versus without VMSs had a significantly higher risk of developing clinically relevant depressive symptoms (multivariable-adjusted hazard ratio, 1.72; 95 % CI 1.39–2.14). VMS severity exhibited a dose-response relationship with depressive symptoms (P for trend
ISSN:0165-0327
1573-2517
DOI:10.1016/j.jad.2024.03.083